Profitable DMD franchise seeks to shed accelerated-approval status; conversion decisions will determine whether the commercial foundation holds or faces withdrawal risk

Sarepta is a commercial-stage company generating over $1.3 billion in annual revenue from its muscular dystrophy franchise, which includes two marketed drugs not yet granted traditional FDA approval that currently carry accelerated-approval status pending conversion based on ongoing evidence.

Sarepta generates over $1.3B in annualized net product revenue from its DMD franchise, reaching operating profitability, while two of its marketed drugs still carry accelerated approvals pending traditional conversion. The single binary: whether FDA grants traditional approval for AMONDYS 45 and VYONDYS 53 based on ESSENCE data plus real-world evidence, given that the confirmatory trial had prior failures. The unusual approval-path risk, converting accelerated status on data that includes a failed trial component, is the primary threat to the commercial base.